The status of CDKN1C expression could also be tested in other cancers as 5-azacytidine plus entinostat regimen has been successfully tested on patients with AML arising after chemotherapy or radiation therapy, breast cancer and colorectal cancer5,7. This evidence concerns the gene CDKN1C and breast cancer.